GlassScriptPhysician profile
Lawrence K Wong
NPI 1295930659
$3,173.70
in general payments reported to CMS, 2019-2025
28 companies · $885 in 2025
The $885 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $57.43 · 2021: $332 · 2022: $497 · 2023: $350 · 2024: $486 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $536.24 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $385.10 | 2019-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $294.01 | 2021-2025 | Lupkynis |
| Amgen INC. | $199.35 | 2019-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $195.92 | 2021-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $166.81 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $130.74 | 2023-2025 | |
| Vantive US Healthcare LLC | $115.87 | 2025 | Renal - Acute |
| Baxter Healthcare | $104.42 | 2019 | |
| Daiichi Sankyo INC. | $97.76 | 2019-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.72 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $86.97 | 2022 | |
| Ardelyx, INC. | $86.57 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $75.20 | 2021-2023 | Rayaldee |
| Mallinckrodt Enterprises LLC | $65.94 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $64.30 | 2019-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $61.47 | 2022-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $53.61 | 2023 | Jardiance |
| Horizon Therapeutics Plc | $50.15 | 2019-2022 | |
| Travere Therapeutics, INC. | $45.90 | 2024-2025 | |
| Scpharmaceuticals INC. | $42.99 | 2025 | |
| Vifor Pharma, INC. | $42.41 | 2019-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $36.99 | 2024-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $35.63 | 2024 | |
| Akebia Therapeutics INC | $28.31 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $24.63 | 2021 | |
| Cormedix INC. | $24.60 | 2024 | Defencath |
| Bard Peripheral Vascular, INC. | $24.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.